Q4 EPS Forecast for Vanda Pharmaceuticals Lifted by Analyst

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Equities researchers at HC Wainwright increased their Q4 2026 EPS estimates for Vanda Pharmaceuticals in a research note issued on Monday, January 5th. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will earn $0.06 per share for the quarter, up from their previous forecast of $0.03. HC Wainwright currently has a “Buy” rating and a $22.00 target price on the stock. The consensus estimate for Vanda Pharmaceuticals’ current full-year earnings is ($1.12) per share.

Several other research firms have also recently weighed in on VNDA. UBS Group reissued a “buy” rating on shares of Vanda Pharmaceuticals in a research report on Monday. Wall Street Zen raised shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday. Weiss Ratings restated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research report on Wednesday, October 8th. B. Riley boosted their target price on shares of Vanda Pharmaceuticals from $11.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday, December 31st. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Vanda Pharmaceuticals in a research report on Wednesday, December 17th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $13.63.

Vanda Pharmaceuticals Price Performance

Shares of NASDAQ VNDA opened at $7.87 on Tuesday. The company has a market capitalization of $465.12 million, a PE ratio of -5.54 and a beta of 0.60. The company has a quick ratio of 3.10, a current ratio of 3.12 and a debt-to-equity ratio of 0.01. The stock’s 50 day moving average price is $5.76 and its 200-day moving average price is $5.13. Vanda Pharmaceuticals has a twelve month low of $3.81 and a twelve month high of $9.60.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings data on Wednesday, October 29th. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.07). Vanda Pharmaceuticals had a negative return on equity of 16.82% and a negative net margin of 39.70%.The firm had revenue of $56.26 million during the quarter, compared to the consensus estimate of $58.73 million.

Institutional Trading of Vanda Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the company. Russell Investments Group Ltd. grew its position in shares of Vanda Pharmaceuticals by 456.6% during the 3rd quarter. Russell Investments Group Ltd. now owns 6,495 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 5,328 shares in the last quarter. CWM LLC increased its stake in Vanda Pharmaceuticals by 424.6% in the 2nd quarter. CWM LLC now owns 9,359 shares of the biopharmaceutical company’s stock worth $44,000 after acquiring an additional 7,575 shares during the last quarter. PVG Asset Management Corp bought a new stake in shares of Vanda Pharmaceuticals during the 1st quarter valued at about $48,000. Quarry LP purchased a new position in shares of Vanda Pharmaceuticals during the third quarter worth about $53,000. Finally, Boothbay Fund Management LLC purchased a new position in shares of Vanda Pharmaceuticals during the third quarter worth about $72,000. 88.14% of the stock is currently owned by hedge funds and other institutional investors.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.